On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion
On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion
复制标题
DOI：
10.1016/j.jprot.2010.03.005
复制
发表时间：
2010-06-16
影响因子：
3.3
通讯作者：
Paez de la Cadena, M.
中科院分区：
文献类型：
--
作者：
Rodriguez-Pineiro, A. M.;Blanco-Prieto, S.;Paez de la Cadena, M.
当前对非小细胞肺癌（NSCLC）新生物标志物的迫切需求促使我们将癌症患者与肺炎或结核等良性肺部疾病患者的血清和胸腔积液样本的蛋白质组进行比较。在 2D-DIGE 之前，通过亲和层析对样品进行预分级，以检测癌症患者中表达改变的蛋白质。总体而言，我们在胸腔积液中发现了更多潜在的生物标志物，胸腔积液比血清更接近受影响的器官。然而，在这两种情况下，主成分分析表明，显着改变的蛋白质模式可以区分疾病组。候选生物标志物包括恶性胸腔积液中增加的蛋白质，如凝溶胶蛋白和金属蛋白酶抑制剂 2，以及其他水平较低的蛋白质，如 S100-A8 和 S100-A9。最有趣的蛋白质是色素上皮衍生因子（PEDF），它与血管生成抑制有关，并且在 NSCLC 患者的血清和胸腔积液中显着过度表达。在二维印迹中，两种液体中均特异性免疫检测到超过 12 种 PEDF 亚型，其中大多数在 NSCLC 中过表达。因此，理想情况下，进一步的验证应该是量化各个 PEDF 同工型，因为可能只有其中一种或某些同工型在癌症过程中发生了改变。 (C) 2010 Elsevier B.V. 保留所有权利。
The current imperative need for new biomarkers of non-small cell lung cancer (NSCLC) prompted us to compare the proteome of serum and pleural effusion samples from cancer patients with those with benign lung diseases as pneumonia or tuberculosis. Samples were prefractionated through affinity chromatography prior to 2D-DIGE to detect proteins with altered expression in cancer patients. Overall, we identified more potential biomarkers in pleural effusion, which is closer to the affected organ, than in serum. Nevertheless, in both cases principal component analysis demonstrated that the pattern of significantly altered proteins discriminates between disease groups.The biomarker candidates comprise proteins increased in malignant pleural effusions as gelsolin and the metalloproteinase inhibitor 2, and others with lower levels as S100-A8 and S100-A9. The most interesting protein was the pigment epithelium-derived factor (PEDF), which is related to angiogenesis inhibition, and was significantly overexpressed both in serum and pleural effusion from NSCLC patients. More than 12 PEDF isoforms were specifically immunodetected in both fluids in 2-D blots, most of them overexpressed in NSCLC. Thus, further validation would be ideally directed to quantify individual PEDF isoforms, as it may be only one or some of them the ones altered in the cancer process. (C) 2010 Elsevier B.V. All rights reserved.